AKT1 and glioblastoma: Given that we saw no bias either way upon combination treatment alongside increased ZOL-1 treatment efficacy, we suggest that co-treatment of GBM cells with picitilisib or MK-2206 can enhance ZOL-1 oncolytic effects and establishes a proof of concept to further evaluate the role of AKT inhibitors in GBM treatment.